Our studies over several years have shown that IGFBP-3 stimulates an oncogenic pathway in which the activation of SphK 1, leading to increased sphingosine-1-phosphate generation, results in the transactivation of EGFR which drives tumor proliferation (12, 13). This evidence concerns the gene IGFBP3 and neoplasm.